Newsroom

GENT, Belgien & TOKIO--(BUSINESS WIRE)--Die H.U. Group Holdings Inc. und ihre hundertprozentige Tochtergesellschaft Fujirebio gaben heute bekannt, dass Fujirebio Europe N.V. ein CE-Zertifikat für den Lumipulse G pTau 217 Plasma-Assay gemäß der Verordnung (EU) 2017/746 über In-vitro -Diagnostika (IVDR) erhalten hat. Dieser CLEIA-Test (Chemilumineszenz-Enzymimmunoassay) ermöglicht die quantitative Bestimmung von an Threonin 217 phosphoryliertem Tau (pTau 217) in humanem Plasma (K2 EDTA). „Mit den...

GAND, Belgique et TOKYO, Japon--(BUSINESS WIRE)--H.U. Group Holdings Inc. et sa filiale à 100 %, Fujirebio, ont annoncé aujourd’hui que Fujirebio Europe N.V. a obtenu le marquage CE pour le test Lumipulse® G pTau 217 Plasma, conformément au règlement (UE) 2017/746 relatif aux dispositifs médicaux de diagnostic in vitro (IVDR). Ce test CLEIA (dosage immunoenzymatique par chimiluminescence) permet la mesure quantitative de la protéine tau phosphorylée en thréonine 217 (pTau 217) dans le plasma hu...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today clarifies the objectives and criteria selected for the analysis of a predictive biomarker associated with NFL-101, its drug candidate for smoking cessation. The objectives associated with the validation of a predictive efficacy biomarker are to strengthen the probability of...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News : NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), société biopharmaceutique développant des médicaments botaniques innovants pour le traitement des addictions, précise aujourd’hui les enjeux et les critères retenus pour l’analyse d’un biomarqueur prédictif associé à NFL-101, candidat-médicament dans le sevrage tabagique. Les enjeux liés à la validation d’un biomarqueur prédictif d’efficacité sont de renforcer la probabilité d...

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 04/05/2026 FR0014000MR3 45 000 57.9715 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 04/05/2026 FR0014000MR3 15 000 57.9946 CEUX EUROFINS SCIENTIFC 529900JEHFM47D...

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against monday.com Ltd. (“monday.com” or the “Company”) (NASDAQ: MNDY) and reminds investors of the May 11, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm ha...

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to 74 classes of mortgage pass-through certificates from Sequoia Mortgage Trust 2026-INV3 (SEMT 2026-INV3). The transaction consists of 1,275 mortgages with an aggregate principal balance of $507.1 million as of the May 1, 2026 cut-off date. The collateral is characterized by a weighted average (WA) original credit score of 768 and moderate borrower equity, with a WA original LTV and WA original CLTV of 70.9%. KBRA’s rating approach in...

NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--Northwell Health, New York’s largest health system, and Matthew Schaefer, the No. 1 overall pick in the 2025 NHL draft and one of New York hockey’s most promising young stars, announced a new relationship today to help cancer patients and their families find moments of joy while going through the most difficult journeys of their lives. For Schaefer – nominated at just 18 years old for the prestigious Calder Memorial Trophy, awarded to the National Hockey Le...

サンフランシスコ--(BUSINESS WIRE)--（ビジネスワイヤ） -- Ouster, Inc.（Nasdaq：OUST）（「Ouster」または「同社」）は、Physical AI向けセンシングおよび認識のリーダーとして、次世代L4 Ouster Siliconを搭載した新しいOSデジタルLiDARセンサー・ファミリー「Rev8」を発表しました。Ouster Rev8は、世界初の特許取得済みネイティブカラーLiDARセンサーを備え、前世代と比べて最大2倍の検出距離と解像度を提供し、機能安全、信頼性、手頃な価格、大規模展開を念頭に設計されています。 L4 Ouster Silicon： Ousterの画期的なL4アーキテクチャーは、LiDARの検出距離と解像度を前世代比で2倍にし、ネイティブ・カラー・センシングを追加するとともに、機能安全に対応するよう設計されています。富士フイルムのカラー・サイエンスを組み込んだ特許取得済みOuster Siliconを基盤とするL4チップは、精緻なカラー・データとハードウェアで実現されるHDRをもたらします。42.9GMACsの処理能力、毎...

旧金山--(BUSINESS WIRE)--(美国商业资讯)-- 物理AI传感和感知领域的领军企业Ouster, Inc. (Nasdaq: OUST)（简称“Ouster”或“公司”）今日发布搭载新一代L4 Ouster Silicon自研芯片的全新OS数字激光雷达传感器系列Rev8。Ouster Rev8采用全球首款获得专利的原生彩色激光雷达传感器，探测距离和分辨率较上一代产品最高提升一倍，专为功能安全、可靠性、经济性和规模化而设计。 L4 Ouster Silicon自研芯片： Ouster的突破性L4芯片架构将激光雷达探测距离和分辨率较上一代提升一倍，新增原生彩色感知能力，并按照功能安全标准设计。这款L4芯片搭载内嵌Fujifilm色彩成像技术的专利级Ouster Silicon芯片，可输出细腻逼真的彩色图像数据和硬件级高动态范围画面。它具备42.9 GMAC的算力，每秒可探测高达20万亿个光子，测量频率达40千赫兹且拥有皮秒级时间精度，每秒可处理最高1040万个点云数据，芯片外数据带宽可达22.4吉比特每秒。L4架构包含128通道版本L4和256通道版本L4 Max。 原生彩...